Melanoma Insights for Professionals

Epizode

• 
  From collaboration to innovation: How multidisciplinary teams and clinical trials are transforming melanoma care 17.07.2026 40min

  In this episode from MIA’s podcast Melanoma Insights for Professionals, our experts explore the critical role of multidisciplinary collaboration in delivering contemporary melanoma care. Hear how melanoma multidisciplinary teams (MDTs) bring together diverse expertise to navigate increasingly complex treatment pathways, discuss challenging cases and identify opportunities for patients to participate in clinical trials.The discussion provides insight into how MDTs operate in practice, the value they bring to patient outcomes, and how collaboration between clinicians and researchers continues to drive progress. The panel also explores why clinical trials remain fundamental to advancing melanoma care, how practice-changing evidence has shaped current standards of treatment, and what emerging developments may define the future of melanoma management.This podcast is suitable for multidisciplinary specialists, clinical trial researchers and other healthcare professionals. REFERENCEGV Long, et al. A phase 2 study of neoadjuvant nivolumab (nivo) + relatlimab (rela) in high-risk stage II cutaneous melanoma (NeoReNi). J Clin Oncol 44, 9502-9502(2026).SPEAKERSProf Alexander van Akkooi - Surgical Oncologist | Melanoma Institute Australia and The University of Sydney Prof Georgina Long AO - Medical Oncologist and Medical Director | Melanoma Institute Australia, The University of Sydney and Royal North Shore HospitalMaria Gonzalez - CEO and former Head of Clinical Trials | Melanoma Institute AustraliaPlease note that this podcast was accurate at the time of recording (June 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.Melanoma Institute Australia’s Education Program⁠ is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.
• 
  Redefining Immunotherapy (Ep. 5): Hype vs Reality: The Future of Immunotherapy 07.06.2026 22min

  In our final episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts discuss the future of immunotherapy, separating hype from reality and exploring the next frontier of cancer treatment. From cellular therapies and personalised cancer vaccines to mRNA technology and biomarker-driven treatment selection, the panel examines the innovations that could reshape melanoma care over the next decade and the challenges that remain before these therapies become routine clinical practice.Led by Prof Georgina Long AO, the panel of experts discuss:why melanoma continues to lead the global immunotherapy revolution the promise and limitations of TIL therapy, TCR-T cells and other cellular therapies how mRNA technology could transform cancer treatment beyond vaccines the rise of personalised cancer vaccines why biomarkers will be critical to the future of precision immunotherapy. Be sure to take a look at our earlier episodes from this series.This special edition vodcast from ⁠Melanoma Institute Australia⁠ is suitable for Medical Oncologists, Oncology Nurses and other health professionals.SPEAKERSProf Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of SydneyProf Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of SydneyA/Prof Ines Silva - Medical Oncologist, Melanoma Institute AustraliaA/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of SydneyPlease note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.This special vodcast is an initiative of ⁠⁠Melanoma Institute Australia⁠⁠ and made possible by an unrestricted educational grant from Bristol Myers Squibb.For more practise-changing education, visit MIA's ⁠⁠Melanoma Education Portal⁠⁠.
• 
  Redefining Immunotherapy (Ep. 4): Melanoma Treatment Strategy: Expert Perspectives 31.05.2026 27min

  In our fourth episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts discuss one of the most rapidly evolving areas in melanoma care: immunotherapy treatment strategy. Drawing on decades of combined clinical experience, the panel explores how treatment paradigms are shifting from decisions around monotherapy versus combination immunotherapy, to increasingly nuanced conversations about treatment duration, rechallenge after progression and retreatment following toxicity. Led by Prof Georgina Long AO, the panel of experts deliver candid expert debate, practical insights and clinical nuance as they explore the evolving landscape of immunotherapy treatment decisions in melanoma care. The panel discusses:     when to stop immunotherapy and why less treatment may sometimes be enough how PET complete metabolic response (CMR) is influencing treatment duration decisions rechallenge strategies after progression or immune-related toxicity managing patients after ipilimumab/nivolumab toxicity the growing move from adjuvant to neoadjuvant treatment approaches. The discussion also tackles the biology behind durable immune responses, the role of surveillance imaging, and the emerging concept of “definitive immunotherapy”, highlighting how melanoma continues to lead the way in reshaping cancer care.Be sure to take a look at our earlier episodes from this series.This special edition vodcast from Melanoma Institute Australia is suitable for Medical Oncologists, Oncology Nurses and other health professionals.SPEAKERSProf Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of SydneyProf Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of SydneyA/Prof Ines Silva - Medical Oncologist, Melanoma Institute AustraliaA/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of SydneyPlease note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.This special vodcast is an initiative of ⁠Melanoma Institute Australia⁠ and made possible by an unrestricted educational grant from Bristol Myers Squibb.For more practise-changing education, visit MIA's ⁠Melanoma Education Portal⁠.
• 
  [Trailer] Redefining Immunotherapy (Ep. 4): Melanoma Treatment Strategy 28.05.2026 1min

  Here's a sneak peak for our upcoming episode of Redefining Immunotherapy: Lessons from Melanoma. In this episode, our experts discuss one of the most rapidly evolving areas in melanoma care: immunotherapy treatment strategy. Look out for Episode 4, Melanoma Treatment Strategy: Expert Perspectives, dropping on Monday 1 June.
• 
  Redefining Immunotherapy (Ep. 3): Immunotherapy Toxicity: Prevention, Early Recognition and Management to Optimise Outcome 24.05.2026 24min

  In our third episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts focus on one of the most important challenges in modern cancer care: immunotherapy toxicity.From subtle early warning signs to life-threatening immune-related adverse events, this episode explores how clinicians can better predict, recognise and manage toxicity while still maximising the life-saving potential of immunotherapy.Led by Prof Georgina Long AO, the panel of experts share real-world insights from decades of combined experience, including:how to educate patients to improve early reporting of symptomswhen to pause treatment and why "less can be more"practical approaches to managing colitis, hepatitis, pneumonitis and neurological toxicitiesthe evolving role of steroids, infliximab and targeted immunosuppressionwhy early intervention can improve both quality of life and survival outcomes. Packed with nuanced clinical discussion, relatable patient scenarios and candid expert debate, this episode delivers valuable insights for healthcare professionals using immunotherapy across melanoma and other cancer settings.Be sure to take a look at our earlier episodes from this series. This special edition vodcast from Melanoma Institute Australia is suitable for Medical Oncologists, Oncology Nurses and other health professionals.SPEAKERSProf Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of SydneyProf Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of SydneyA/Prof Ines Silva - Medical Oncologist, Melanoma Institute AustraliaA/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of SydneyPlease note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.This special vodcast is an initiative of Melanoma Institute Australia and made possible by an unrestricted educational grant from Bristol Myers Squibb.For more practise-changing education, visit the Melanoma Education Portal.
• 
  Redefining Immunotherapy (Ep. 2): Predict, Treat, Monitor: The Quest for Smarter Immunotherapy Decisions 17.05.2026 23min

  In our second episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts tackle one of the biggest challenges in modern oncology: how do we make smarter immunotherapy decisions for individual patients?The panel explores the real-world factors that shape treatment selection in advanced melanoma; from tumour burden, brain and liver metastases, and BRAF mutation status, to patient age, fitness and comorbidities. They unpack the evolving role of combination immunotherapy,including PD-1 monotherapy, ipilimumab/nivolumab and newer LAG-3 combinations, while weighing the balance between efficacy and toxicity.The discussion also dives into the promise and limitationsof biomarkers such as PD-L1, tumour mutational burden (TMB), interferon gamma signatures and MSI-high status, and examines why predicting response to immunotherapy remains one of the field’s greatest challenges.Blending practical clinical insight with emerging research,this episode offers a thoughtful and highly relevant discussion on personalising immunotherapy in the pursuit of more durable outcomes, and ultimately, cure.This vodcast is suitable for Medical Oncologists, Oncology Nurses and other health professionals. SPEAKERSProf Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of SydneyProf Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of SydneyA/Prof Ines Silva - Medical Oncologist, Melanoma Institute AustraliaA/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of Sydney Please note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.This special vodcast is an initiative of Melanoma Institute Australia and was made possible by an unrestricted educational grant from Bristol Myers Squibb.
• 
  Redefining Immunotherapy (Ep. 1): Beyond the Tumour: Rethinking Cancer in the Immunotherapy Era 11.05.2026 25min

  In this opening episode of our special vodcast series “Redefining Immunotherapy: Lessons from Melanoma”, our world-leading Medical Oncologists set the stage for a compelling five-part series exploring how immunotherapy is reshaping cancer care.Led by Prof Georgina Long AO, this engaging discussion unpacks how tumours evade the immune system, how checkpoint inhibitors work and why responses can be so durable. They also discuss how immunotherapy differs from chemotherapy and targeted therapy—shifting treatment from directly attacking cancer to activating the body’s own immune response.Drawing on both clinical experience and emerging research, this episode sets the foundation for the series ahead—challenging traditional paradigms and offering a practical, clinician-focused lens on how immunotherapy is reshaping cancer care across tumour types.This vodcast is suitable for Medical Oncologists, Oncology Nurses and other health professionals. SPEAKERSProf Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of SydneyProf Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of SydneyA/Prof Ines Silva - Medical Oncologist, Melanoma Institute AustraliaA/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of Sydney Please note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.This special vodcast is an initiative of Melanoma Institute Australia and was possible by an unrestricted educational grant from Bristol Myers Squibb.For more practice-changing education, visit MIA's Melanoma Education Portal.
• 
  After the diagnosis: Getting follow-up care right in melanoma 02.12.2025 29min

  As patients transition from treatment to routine monitoring, clinicians play a crucial part in detecting recurrence early, supporting wellbeing, and guiding patients through survivorship.In the latest episode of our podcast Melanoma Insights for Professionals, we explore the essential role of follow-up care in melanoma management.Our multidisciplinary experts provide an engaging and practical discussion to help strengthen your approach to melanoma follow-up care and covers: why follow-up schedules vary and how clinicians tailor them stage-specific approaches for all stages of melanoma the role of dermatological surveillance and patient education supporting psychological wellbeing, including managing scanxiety.This podcast is suitable for Surgeons, Dermatologists, Skin Cancer GPs, GPs, Nurses and other health professionals.If you require a Statement of Completion for your CPD records, please listen to this podcast via the the Melanoma Education Portal.SPEAKERSA/Prof Robyn Saw - Surgical Oncologist, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of SydneyDr Mary-Ann El Sharouni - Dermatologist, Melanoma Institute Australia and Sydney Melanoma Diagnostic Centre, Royal Prince Alfred HospitalClaire Gore - Senior Clinical Psychologist, Melanoma Institute AustraliaRESOURCES MIA’s Patient Resources (including Guides like Melanoma Prevention and Early Detection Guide and Patient Fact Sheet such as Scanxiety and How to cope with the fear of melanoma returning)Cancer Council’s SunSmart Global UV appPlease note that this presentation was accurate at the time of recording (November 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.
• 
  Overdiagnosis or early detection? The controversy of melanoma in situ 21.10.2025 40min

  As melanoma in situ (MIS) diagnoses rise, concerns about overdiagnosis are growing — with real implications for patients, clinicians and the health system.In this episode of our podcast Melanoma Insights for Professionals, experts from dermatology, pathology, psychology and research come together to explore the drivers of overdiagnosis, the psychological impact of an MIS label, and the role of emerging diagnostic tools and data.This podcast is suitable for multidisciplinary specialist, primary care physicians and other healthcare professionals.SPEAKERSDr Peter Ferguson - Pathologist, Royal Prince Alfred Hospital and Melanoma Institute AustraliaDr Christoph Sinz - Confocal Microscopy Dermatologist, Melanoma Institute AustraliaClaire Gore - Senior Clinical Psychologist, Melanoma Institute AustraliaDr Ismael Vergara - Senior Computational Biologist, Melanoma Institute Australia | Adjunct Senior Lecturer, The University of SydneyRESOURCES MIA’s Patient Guides (e.g. Your Guide to Melanoma In-Situ) MIA’s Patient Fact Sheets (e.g. Scanxiety)REFERENCESBjørch MF, Gram EG, Brodersen JB Overdiagnosis in malignant melanoma: a scoping review BMJ Evidence-Based Medicine 2024;29:17-28.Cramb SM, Duncan EW, Aitken JF, Soyer HP, Mengersen KL, Baade PD. Geographical patterns in melanoma incidence across Australia: Can thickness differentials reveal the key drivers? Ann Cancer Epidemiol 2020;4:11Daniel Lindsay, Katy J L Bell, Catherine M Olsen, David C Whiteman, Thanya Pathirana, Louisa G Collins, Estimating the magnitude and healthcare costs of melanoma in situand thin invasive melanoma overdiagnosis in Australia British Journal of Dermatology, 2024;191(6): 906–913,Patel VR, Roberson ML, Pignone MP, Adamson AS. Risk of Mortality After a Diagnosis of Melanoma In Situ. JAMA Dermatol.2023;159(7):703–710.Please note that this podcast was accurate at the time of recording (August 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA's Education Program is proudly supported through unrestricted educational grants from Bristol Myers Squibb, MSD and HEINE.
• 
  Utilising melanoma risk prediction tools for newly diagnosed patients 15.08.2025 31min

  In this episode, we explore how melanoma risk prediction tools are transforming clinical decision-making for newly diagnosed patients. These tools, developed by Melanoma Institute Australia and freely available at melanomarisk.org.au, help clinicians tailor care and improve outcomes.Our multidisciplinary experts provide practical guidance on using tools to predict sentinel node metastasis, recurrence risk and more. Through real-world case examples and expert insights, this episode offers valuable strategies for integrating personalised risk assessment into your practice.This podcast is suitable for multidisciplinary specialists, primary care physicians and other healthcare professionals.Resources:Melanoma Risk Prediction CalculatorsMIA's Patient ResourcesMelanoma Education PortalSpeakers:Prof Anne Cust - Cancer Epidemiologist and Faculty Member, Melanoma Institute Australia | Interim Director, Daffodil Centre | Chair, Cancer Council National Skin Cancer CommitteeA/Prof Alex Varey - Plastic and Reconstructive Surgeon, Melanoma Institute Australia and Westmead Hospital | Clinical Associate Professor, The University of SydneyA/Prof Linda Martin - Director of Dermatology Services, Melanoma Institute Australia | Staff Specialist, Sydney Children’s Hospital | Associate Professor of Dermatology, University of NSWPlease note that this podcast was accurate at the time of recording (August 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.
• 
  Sentinel node biopsy in melanoma: Still recommended in 2025? 20.06.2025 36min

  In this episode of Melanoma Insights for Professionals, we explore the evolving role of sentinel node biopsy (SNB) in melanoma management—particularly in the modern context of perioperative drug therapy.Our expert panel unpacks current evidence, shifting guidelines and real-world clinical considerations influencing when and why SNB is performed. Topics include prognostic value, surgical decision-making, pathological assessment, patient-centred perspectives and the impact of new treatment approaches on traditional staging practices.This podcast is produced by Melanoma Institute Australia and is suitable for multidisciplinary specialists, primary care physicians and other healthcare professionals.RESOURCES: Melanoma Risk Prediction Tools Patient brochure on SNB MIA's Melanoma Education Portal (Clinicians only)SPEAKERS:A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of SydneyA/Prof Robyn Saw - Surgical Oncologist, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of SydneyA/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of SydneyDr Robert Rawson - Pathologist, Melanoma Institute Australia |Tissue Pathology Staff Specialist, Royal Prince Alfred HospitalPlease note that this podcast was accurate at the time of recording (May 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA’s Education Program is proudly supported through unrestricted educational grants from Bristol Myers Squibb, MSD and HEINE.
• 
  Integrating AI in melanoma care 14.05.2025 30min

  In this episode of Melanoma Insights for Professionals, we explore the cutting-edge role of artificial intelligence (AI) in diagnosing melanoma.Join Dermatologists Prof Pascale Guitera and Prof Victoria Mar and Pathologist Dr Nigel Mayer as they unpack how AI is transforming clinical practice—from lesion detection and triage to deep learning in pathology and improving clinical education. Discover the promise, limitations and ethical considerations of integrating AI into dermatology and pathology, and hear what's next on the horizon for both clinicians and patients.This podcast is suitable for multidisciplinary specialists, primary care physicians, researchers and other healthcare professionals.SPEAKERSProf Pascale Guitera - Dermatologist and Education Committee Chair, Melanoma Institute Australia | Director, Sydney Melanoma Diagnostic Centre at Royal Prince Alfred Hospital Prof Victoria Mar - Director, Victorian Melanoma Service at The Alfred | Professor of DermatoOncology, the School of Public Health and Preventive Medicine, Monash UniversityDr Nigel Maher - Pathologist, Melanoma Institute Australia | Chair of the AI Working Group, Royal College of Pathologists of AustralasiaPlease note that this podcast was accurate at the time of recording (May 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.For more practice-changing clinical education, visit the Melanoma Education Portal.
• 
  The future of melanoma detection and management: Perspectives from world-leading clinicians 05.11.2024 39min

  In this special podcast recorded from the 2024 Australasian Melanoma Conference, we hear from our international keynote speakers, Prof Susan Swetter and Prof Olivier Michelin, about what excites them in the field of melanoma research. Interviewed by AMC2024 Co-Chairs, Prof Georgina Long AO and Prof Richard Scolyer AO, our guests provide their multidisciplinary perspectives and highlight the importance of working together to make an impact in melanoma prevention and patient care. Dermatologist Prof Swetter discusses the evolving role of AI in dermatology and the clinical diagnosis of melanoma, and highlights the opportunity for improved prevention strategies in the US to reduce the incidence of melanoma. Prof Michelin explores how we’re tackling advanced melanoma, in particular to maximize our current treatment tools and manage drug toxicities. He also discusses expanding access to neoadjuvant therapies and the potential of TIL therapies, alongside AI advancements in histopathological diagnosis to personalise treatment approaches. This podcast is suitable for multidisciplinary healthcare professionals and researchers. SPEAKERS Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney |2024 Joint Australian of the Year Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney |2024 Joint Australian of the Year Prof Susan Swetter - Professor of Dermatology, Co-Director of the Pigmented Lesion/Melanoma and Cutaneous Oncology Programs, Stanford University Medical Center and Cancer Institute | Chair, National Comprehensive Cancer Network Melanoma Panel Prof Olivier Michelin - Chair, Department of Oncology and the Precision Oncology Service, Geneva University Hospital | Co-Director, Swiss Cancer Centre Léman| Vice-Coordinator, Translational Research Centre in Onco-Hematology Please note that this podcast was accurate at the time of recording (October 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.
• 
  Unveiling melanoma research: Shaping the future with innovative research infrastructure 02.09.2024 29min

  Comprehensive infrastructure is essential to driving research progress and improving patient care. In this podcast, A/Prof Sydney Ch’ng leads an insightful discussion on the groundbreaking research infrastructure that underpins the many groundbreaking achievements at Melanoma Institute Australia. The discussion highlights the Institute’s clinical trial program, translational research, biospecimen bank and melanoma research database, offering a closer look at the critical elements driving progress. This podcast is suitable for multidisciplinary healthcare professionals, researchers and clinical trials staff. SPEAKERS A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Helen Rizos - Cancer Cell Biologist and Research Lead in the Faculty of Medicine, Health and Human Sciences at Macquarie University | Faculty Member, Melanoma Institute Australia A/Prof Serigne Lo - Senior Biostatistician, Melanoma Institute Australia | Associate Professor of Biostatistics, The University of Sydney Maria Gonzalez - Director of Clinical Care, Melanoma Institute Australia Dr Nicole Caixeiro - Head of the Biospecimen Bank, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (August 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. LINKS 2024 Australasian Melanoma Conference Melanoma Education Program MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.
• 
  Transforming cancer care: Neoadjuvant therapy and trials in melanoma care 03.06.2024 35min

  Neoadjuvant immunotherapy is transforming patient care in the field of melanoma. New research recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting is set to change melanoma treatment protocols globally, and likely to have significant impact on treatment for other cancers too. In this podcast, A/Prof Matt Carlino leads an engaging discussion with MIA’s Prof Georgina Long AO, A/Prof Alex Menzies and A/Prof Alex van Akkooi as they discuss the pivotal results from the NADINA trial and how this will undoubtedly change the standard of care for Stage III melanoma patients. They also discuss the practical implications for implementing this treatment regime, including relevant patient populations, toxicity, impacts for surgery and future directions. This podcast is suitable for Medical Oncologists, Surgical Oncologists, Pathologists, Researchers, GPs Oncology Nurses and other healthcare professionals. It is produced by Melanoma Institute Australia. SPEAKERS A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney PUBLICATIONS Blank C, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med 2024. DOI: 10.1056/NEJMoa2402604 Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813-823. FURTHER EDUCATION Podcast: Neoadjuvant immunotherapy: Revolutionising melanoma treatment Video: The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Conference: 2024 Australasian Melanoma Conference Please note that this podcast was accurate at the time of recording (2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.
• 
  Current and emerging biomarkers for melanoma care 21.05.2024 33min

  Biomarkers are revolutionising our understanding of melanoma by providing valuable information about a patient's unique tumour characteristics which can help guide clinical decision making. In this podcast, A/Prof Alex Menzies leads a multidisciplinary discussion on the current state of biomarker application and future prospects of biomarkers in melanoma care. They discuss emerging liquid biomarkers, such as ctDNA, MIA’s personalised immunotherapy platform that is trying to predict the likelihood of response and select patients for treatment, and the role of the gut microbiome as a potential biomarker in response and toxicity. This podcast from Melanoma Institute Australia is suitable for Medical Oncologists, Surgical Oncologists, Researchers, GPs and other healthcare professionals. LINKS: 2024 Australasian Melanoma Conference Melanoma Risk Prediction Tools Melanoma Education Portal SPEAKERS A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Ines Silva - Medical Oncologist, Melanoma Institute Australia and Blacktown Hospital | Research Scientist, Melanoma Institute Australia and The University of Sydney Prof Helen Rizos - Cancer Cell Biologist and Research Lead in the Faculty of Medicine, Health and Human Sciences at Macquarie University | Faculty Member, Melanoma Institute Australia A/Prof James Wilmott - Senior Scientist, Charles Perkins Centre, The University of Sydney| Faculty Member, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (April 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.
• 
  Spotlight on mucosal melanoma: Head and neck 02.04.2024 41min

  Mucosal melanoma is a rare and aggressive form of melanoma that arises from the mucous membrane. In this podcast, we focus on mucosal melanoma of the head and neck. Led by A/Prof Sydney Ch’ng, our multidisciplinary experts discuss how it differs from cutaneous melanoma, staging of mucosal melanoma, management of the disease and future treatments. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, Surgical Oncologists, Dermatologists, Medical Oncologists, Pathologists, GPs, Nurses and other healthcare professionals. Register now to attend the 2024 Australasian Melanoma Conference, hosted by Melanoma Institute Australia. SPEAKERS A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Raewyn Campbell - Rhinologist and Anterior Skull Base Surgeon |Associate Professor, Macquarie University Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney Please note that this podcast was accurate at the time of recording (March 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.
• 
  Dealing with diagnostic uncertainty and borderline pathology 29.11.2023 41min

  Diagnostic uncertainty in the context of cutaneous melanoma can have significant impact on patient care. In this podcast, our multidisciplinary experts, led by Dr Adrian Quek, discuss the challenges faced in classifying melanocytic lesions that fall into a diagnostic grey area, and explore the terminology, evolving classifications and the impact of diagnostic uncertainty on patient outcomes. From molecular changes to clinical perspectives, this engaging discussion provides a comprehensive exploration of the complexities surrounding borderline lesions, and emphasises the need for experienced multidisciplinary professionals in ensuring accurate diagnoses and ideal management. This podcast is suitable for Pathologists, Dermatologists, Surgeons, Oncologists, GPs and other healthcare professionals. Register now to attend the ⁠2024 Australasian Melanoma Conference⁠, hosted by Melanoma Institute Australia. RESOURCES Video: How to diagnose borderline cutaneous melanocytic lesions Paper: Yeh, I. New and evolving concepts of melanocytic nevi and melanocytomas. Modern Pathology. 2020;33:1-14. Nevus/Melanocytoma/Melanoma: An Emerging Paradigm for Classification of Melanocytic Neoplasms?. Arch Pathol Lab Med. 2011;135(3): 300–306. SPEAKERS Dr Adrian Quek - Skin Cancer GP, Melanoma Institute Australia and Chatswood Skin Cancer Clinic A/Prof Robyn Saw - General Surgeon, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of Sydney Prof H. Peter Soyer - Chair in Dermatology and Director of the Dermatology Research Centre, The University of Queensland Dr Andrew Colebatch - Staff Specialist in Anatomical Pathology, Royal Prince Alfred Hospital Please note that this podcast was accurate at the time of recording (November 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. For more clinical education from MIA, sign up to the Melanoma Education Portal.
• 
  Melanoma: When do I scan? 27.09.2023 42min

  With the advent of effective medical therapies for melanoma, a pertinent question has arisen: When should we scan our patients? In this podcast, our multidisciplinary experts, led by A/Prof Sydney Ch’ng, discuss the balance of whether we should be more aggressive in our pursuit of identifying potential metastases or exercise caution to avoid unnecessary scans, radiation exposure and patient anxiety. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists, Surgeons, GPs, Oncology Nurses and other healthcare professionals. RESOURCES Melanoma Risk Prediction Tools SPEAKERS A/Prof Sydney Ch’ng -  Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia, Associate Professor of Surgery, The University of Sydney  A/Prof Alexander Menzies -  Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney Dr Edward Hsiao - Radiologist and Nuclear Medicine Specialist, Mater Imaging Dr Kevin London - Nuclear Medicine Specialist, The Children’s Hospital at Westmead | Clinical Senior Lecturer, The University of Sydney Please note that this podcast was accurate at the time of recording (September 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. For more practice-changing education, visit our Melanoma Education Portal. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. 
• 
  When to recommend a sentinel node biopsy in melanoma 07.07.2023 33min

  Sentinel node biopsy (SNB) plays a key role in assessing the prognosis of melanomas. In this fireside chat from our new SNB Training Program (Sentinel Node Biopsy: From guidelines to practice), MIA’s Prof Georgina Long AO, Prof John Thompson AO and A/Prof Sydney Ch’ng discuss: the history of SNB in the management of melanoma its current role in the stratification of patients into those who may benefit from adjuvant therapies verses those for whom active surveillance is more appropriate other potential benefits of SNB, including the likelihood of SNB itself reducing the risk of nodal recurrence. This podcast is suitable for Surgeons, Medical Oncologists, General Practitioners and other healthcare professionals. SPEAKERS A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Senior Surgeon, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (July 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.